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Abstract
Background: Reverse transcriptase is a major drug target in highly active antiretroviral therapy (HAART) against HIV, which
typically comprises two nucleoside/nucleotide analog reverse transcriptase (RT) inhibitors (NRTIs) in combination with a
non-nucleoside RT inhibitor or a protease inhibitor. Unfortunately, HIV is capable of escaping the therapy by mutating into
drug-resistant variants. Computational models that correlate HIV drug susceptibilities to the virus genotype and to drug
molecular properties might facilitate selection of improved combination treatment regimens.
Methodology/Principal Findings: We applied our earlier developed proteochemometric modeling technology to analyze
HIV mutant susceptibility to the eight clinically approved NRTIs. The data set used covered 728 virus variants genotyped for
240 sequence residues of the DNA polymerase domain of the RT; 165 of these residues contained mutations; totally the
data-set covered susceptibility data for 4,495 inhibitor-RT combinations. Inhibitors and RT sequences were represented
numerically by 3D-structural and physicochemical property descriptors, respectively. The two sets of descriptors and their
derived cross-terms were correlated to the susceptibility data by partial least-squares projections to latent structures. The
model identified more than ten frequently occurring mutations, each conferring more than two-fold loss of susceptibility for
one or several NRTIs. The most deleterious mutations were K65R, Q151M, M184V/I, and T215Y/F, each of them decreasing
susceptibility to most of the NRTIs. The predictive ability of the model was estimated by cross-validation and by external
predictions for new HIV variants; both procedures showed very high correlation between the predicted and actual
susceptibility values (Q
2=0.89 and Q
2
ext=0.86). The model is available at www.hivdrc.org as a free web service for the
prediction of the susceptibility to any of the clinically used NRTIs for any HIV-1 mutant variant.
Conclusions/Significance: Our results give directions how to develop approaches for selection of genome-based optimum
combination therapy for patients harboring mutated HIV variants.
Citation: Junaid M, Lapins M, Eklund M, Spjuth O, Wikberg JES (2010) Proteochemometric Modeling of the Susceptibility of Mutated Variants of the HIV-1 Virus to
Reverse Transcriptase Inhibitors. PLoS ONE 5(12): e14353. doi:10.1371/journal.pone.0014353
Editor: Jean Peccoud, Virginia Tech, United States of America
Received April 27, 2010; Accepted November 10, 2010; Published December 15, 2010
Copyright:  2010 Junaid et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support was received from Uppsala University (KoF 07), Stiftelsen La ¨kare mot AIDS Forskningsfond and Wiberg’s foundation. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JEW, OS and ME hold shares in Genetta Soft, a Swedish limited company devoted to software developments. This does not alter the
authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: Jarl.Wikberg@farmbio.uu.se
Introduction
The threat to human health posed by the HIV/AIDS epidemic
is increasing and represents now the third largest cause of death by
infectious disease in the world [1]. Since its recognition in 1981
more than 25 million people died from AIDS; only in 2008, 2
million people died, 33 million were living with HIV, and 2.7
million became infected with the virus [2]. Although the access to
highly active antiretroviral therapy (HAART) has reduced the
mortality in the Western world, an estimated 38,000 [estimated
range 30,000–46,000] of approximately 2.25 million [1.9–2.6
million] people with HIV in the North America, Western and
Central Europe died from AIDS in 2008 [2].
When given as mono-therapy, none of the available antiretro-
virals is able to suppress HIV replication for any extended period
of time. HAART comprises combinations of three or more drugs
that aim to target HIV in different ways. First-line treatments
include two nucleotide/nucleoside analog reverse transcriptase
(RT) inhibitors (NRTIs) in combination with a non-nucleoside RT
inhibitor (NNRTI) or a protease inhibitor [3]. RT is the sole
enzyme producing double-stranded DNA from the single-stranded
RNA genome, which is an essential step in the virus’ replication
[4–6]. NRTIs are analogs of nucleotide substrates that lack the 3-
OH group present in the four natural deoxyribonucleotides.
NRTIs are phosphorylated by cellular kinases to form 59-
triphosphates, which are used by HIV-RT as substrates and
incorporated in the extending DNA chain [4,6]. NRTIs thereby
act as chain terminators, blocking further elongation of the DNA
[7]. Eight NRTIs have been approved for clinical use: Zidovudine
(AZT), Didanosine (ddI), Zalcitabine (ddC), Tenofovir (TDF),
Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), and
Stavudine (d4T).
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people with HIV, drug resistant virus variants emerge often.
Development of resistance is primarily due to the high viral
replication rate (estimated to 10
9 to 10
10 HIV virions per day in an
average infected person [8]) and the lack of fidelity of RT with an
estimated mutation rate of ,5610
25 per base per generation [9].
There are two distinct mechanisms for development of resistance
to NRTIs. The first is by mutations that primarily cause steric
hindrance, decreasing the rate of incorporation of the NRTI into
the elongating DNA chain. The other is by mutations that increase
phosphorolysis leading to removal of already incorporated chain-
terminating inhibitors from the DNA, thereby allowing reverse
transcription to continue.
When first-line therapy fails, the treating physician needs to
select a new regimen from multiple alternative possible drug
combinations. Since anti-HIV drugs acting at the same target and
binding site are rather similar in their molecular properties, cross-
resistance is common and a new regime cannot be based on the
assumption that the virus will be susceptible to the drugs
remaining in the therapeutic arsenal. Therefore, resistance testing
has become an important tool in management of HIV. Such
testing can be performed either by sequencing the viral genes
coding for the drug targets (genotypic resistance testing), or by
measuring viral activity in the presence and absence of a drug
(phenotypic resistance testing). Genotypic assays are much faster
and less expensive than the phenotypic ones, but sequence data
provide only indirect evidence of resistance and interpretation is
difficult for complex mutational combinations.
Several types of statistical and machine learning techniques
have been proposed for finding relationships between mutations in
the HIV genome and phenotypic drug susceptibility. These
include support vector regression [10–12], least-squares regression
[12], artificial neural networks [12,13], decision trees [12], and
non-linear regression methods [14]. However, all these models
considered only one drug at a time. Hence the predictions afforded
by them did not incorporate any information on similarities and
differences in the structural and physicochemical properties of the
antiretrovirals. This is unfortunate as it is these properties that
determine the similarities and differences in a drug’s interaction
with drug-sensitive and drug-resistant virus variants. The models
are therefore not optimal for explaining cross-resistance and they
are unable to extrapolate to new anti-HIV agents. Moreover, in
the previous modeling studies mutations were represented from
the amino acid letter codes as binary indicator variables, rather
than being based on quantitative descriptions of molecular
properties of the mutated sequence residues that are relevant for
drug-protein interactions (e.g. amino acid size and shape,
hydrophobicity, charge, etc.). For this reason the models have
limited ability to generalize and predict the effect of less common
mutations on virus-drug interactions.
It is important to realize that in vitro susceptibility is only one of
the factors to consider for drawing clinical inferences. Models have
earlier also been developed to predict therapy outcome from virus
genotype using clinical markers (viral load and CD4
+ cell count),
data on drug combinations in previously failed treatment
regimens, and patient data (age, gender, mode of virus
transmission, and adherence), as additional parameters in the
modeling [15,16]. However, these models still do not include any
structural or physico-chemical data and hence cannot extrapolate
to new mutations and novel drugs. Although the models show fair
predictive ability (the accuracy of EuResist prediction engine being
76% when the full feature set is available for the prediction)
presumably because of the inability to generalize to new mutations
and drugs, these models do not include recently approved drugs
for which less clinical data has been collected, such as for example
the HIV protease inhibitors darunavir and tipranavir.
For quite some time we have been developing a multivariate
modeling approach, termed proteochemometrics (PCM), that can
perform concomitant analysis of the interactions of multiple
proteins with multiple ligands. In PCM interaction activity data
are correlated to the physicochemical and structural descriptions
of proteins and ligands and their-derived protein-ligand cross-
description, using a suited multivariate data modeling technique.
In this way interpretable and predictive interaction models are
created that are able to generalize to new protein-ligand
combinations, and to new proteins and new ligands [17]. We
have previously applied PCM for the analysis of drug interactions
with different classes of G-protein coupled receptors, [18–24],
antibody-antigen interactions [25], cleavability of protease sub-
strates [26], and HIV resistance to protease inhibitors [27]. Here
we aimed to create a generalized PCM model for predicting the
susceptibility of mutated HIV variants to the clinically used
NRTIs. The approach presented here to model susceptibility of
antiretrovirals might find use in genome-based optimization of
HIV therapy.
Results
Development and evaluation of the PCM model
The data set used herein comprised 728 HIV variants with
unique RT sequences, covering phenotypic assays for eight
NRTIs; in total the data set comprised 4,495 drug-RT
combinations. As detailed in the Methods section, the eight NRTIs
of the study were characterized by seven principal components
derived from 58 molecular descriptors representing properties
related to molecular geometry, flexibility, and the ability of the
inhibitor to form different types of non-covalent interactions
(Table S1). In the following, these seven principal components will
be denoted I descriptor block. The 165 mutated positions in the
RT sequences were each encoded by three physicochemical z-
scale descriptors, totally giving 16563=495 variables (R descrip-
tor block). The ability for inhibitor-specific interactions of HIV
mutants was described by inhibitor-RT cross-terms (I6R block)
and eventual cooperative effects of sequence mutations were
represented by cross-terms between RT descriptors (R6R block).
Several models of varying complexity were created from these
descriptions in order to find the model that provided the highest
predictive ability and best interpretability.
Model-1 included only inhibitor and RT descriptors (I and R
blocks, 7+495=502 X variables); Model-2 used inhibitor and RT
descriptors together with inhibitor-RT cross-terms (I, R and I6R
blocks, 502+76495=3,967 X variables); Model-3 used additionally
1,128 intra-RT cross-terms (i.e. I, R, I6R, and R6R blocks,
3,967+1,128=5,095 X variables). The logarithmically trans-
formed change in susceptibility (log fold-decrease in susceptibility,
here abbreviated logFDS) was used as the response (y) variable.
Correlation of the X variables to y was performed by partial least-
squares projections to latent structures (PLS).
Model performances are summarized in Table 1. Model-1 could
only partially explain the variation in inhibitor-RT susceptibility,
the squared correlation coefficient (R
2) being 0.57. Model-2
performed substantially better; the R
2 being 0.92. These results
were expected since Model-1 used merely a linear combination of
drug and RT descriptors and hence could explain only the linear
part of interactions (i.e. mutations that lead to cross-resistance).
Due to the cross-terms, Model-2 can locate inhibitor-RT mutant
property combinations that lead to decrease of mutated virus
susceptibility to one or few of drugs, while showing lower influence
Modeling of RT
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between the two R
2 values indicates a high degree of non-linearity
in inhibitor-RT interactions, which results in differing resistance
profiles for the different NRTIs.
Model-2 was used to identify the most influential RT descriptors.
Of the 495 descriptors, 48 obtained variable importance in
projection (VIP) values larger than one and were used to choose
intra-RT cross-terms (see Methods for explanation of VIP and for
further details on selection of intra-RT cross-terms). Adding intra-
RT cross-terms (Model-3) gave a further improvement, thus
confirming the existence of cooperative effects of mutations in
the transcriptase in the development of resistance.
For all three models, the predictive ability, as assessed by 7-fold
cross-validation, was very close to the goodness of fit; for Model-3
the cross-validated squared correlation coefficient Q
2 was as high
as 0.89. However, since the results of cross-validation were used in
model optimization (i.e. selecting scaling weight for cross-terms
and number of extracted PLS components) there is a risk for a bias
in the Q
2 estimate, and we wanted to ascertain that these high Q
2
values were not overoptimistic. To this end we performed external
predictions by building the models on the data for only 70% (503
of 728) of RT sequences and setting aside the remaining 225
sequences as an independent test-set. As seen from Table 1, the
external prediction results correlate well with the goodness of fit
and cross-validation results for the three models; the margin
between R
2 and Q
2
ext is 0.09 or less and the margin between Q
2
and Q
2
ext is as small as 0.02–0.04. The difference between the
goodness of fit and the predictive ability of a PLS model can be
seen as a measure for the risk of having chance-correlations with
irrelevant descriptors in the model, which further on could give
rise to erroneous interpretations of the physical relationships
underlying the model. Alternatively the difference could result
from the presence of outliers in the data-set, which would also bias
the interpretations [28]. The small differences between these
measures for all our three models verify that they can be used
reliably for interpretations.
The performance of Model-3 is summarized in Table 2,
presenting the root mean squared error of prediction (RMSEP)a s
well as the first quartile (Q1), median, and third quartile (Q3)o f
the absolute values of prediction errors for each of the eight
inhibitors. As seen from the table, the average RMSEP is 0.25
logarithmic units, the best results being obtained for ddI, ddC,
d4T, ABC, TDF, and FTC. The average Q1 is 0.07, the median
0.13, and the Q3 0.23 logarithmic units. The performance of
Model-3 is also illustrated graphically in Figure 1. Inspection of
the figure reveals that altogether about 94% of the predictions fall
in the area between the oblique grey lines indicating an error of
60.5 logarithmic units. In less than 1% of the cases (13 out of
1372) the prediction errors exceed 61 log units (not shown
graphically). A closer inspection of the data presented in Figure 1
reveals that eight of the thirteen largest mispredictions occurred
for 3TC, while five occurred for AZT. A feasible explanation for
this is that for these two inhibitors the FDS values often exceeded
the upper limit of the assay, which we had approximated to
FDS=200 for the sake of the modeling (see Methods). Obviously
this may lead to over or underestimations of the impact of
mutation combinations on drug susceptibility in heavily mutated
virus variants. For 3TC an additional explanation is that this drug
is highly influenced by mutations of a single residue, M184, to V
or I. A point mutation at this position is present in more than half
the data-set sequences and brings about an, on the average, 30-
to 100-fold loss of susceptibility for 3TC (vide infra). Inspection of
the sequences of the four isolates harboring this mutation, but
which retained high susceptibility to 3TC, indicates that although
V (Valine) was the dominant amino acid at position 184,
genotyping had detected also the wild type amino acid at this
position; thus the virus isolate actually contained a mixture of
several strains. Similarly, in three of the four virus isolates that
were predicted falsely to be susceptible to 3TC, genotyping along
with the wild type amino acid M identified also the mutant
M184V. Thus, the mispredictions can be explained by the
discrepancy between the results of genotype and phenotype
assays; in some cases the genotypic assay identified M as the
prevailing amino acid but in the phenotypic assay the dominant
amino acid was actually V, while in some other cases the situation
was the opposite.
Analyzing the PLS regression equation further reveals that the
over-predicted FDS for isolate 75739 versus AZT (shown as the
AZT-75739 encircled point in bottom right corner of Figure 1)
arises mainly due to an F77L mutation. All virus variants in the
work-set bearing this substitution are AZT resistant (logFDS=1.7–
2.3). Moreover, the RT of isolate 75739 contains several atypical
mutations, such as T215H, which is not present in any of the
work-set sequences. Since histidine is more hydrophilic than the
amino acids that predominate at this sequence position (i.e. T, Y,
and F), the 75739 isolate resides outside the modeled physico-
chemical space. Accordingly the model derives the estimate for the
isolate by extrapolation. It is also appropriate here to mention that
PLS modeling provides tools for detection of outliers to identify
situations when predictions must be used with caution. This
includes the distance-to-model, DModX, criterion [29], which for
the AZT-75739 pair exceeded grossly the critical value in the
model; the DModX (normalized) was 1.83; the critical value (at the
default significance level of 0.05) was 1.11.
The few discrepancies observed are not unique to our approach
and have been reported previously for genotype/phenotype data
[12] and even in between different phenotypic assays [30]. It is not
expected that the influence of rare mutations should be possible
always to be fully accounted for in statistical modeling. Still,
despite the few mispredictions, the high Q
2 and Q
2
ext values of our
model manifest its robustness and suggest that quantitative
assessment can be done on the impact of RT mutations on the
Table 1. Performance of proteochemometric models for prediction of HIV-1 RT drug susceptibility.
Model Descriptor blocks Goodness of fit (R
2) Predictive ability (Q
2) External predictions (Q
2
ext)
Model-1 I, R 0.57 0.55 0.51
Model-2 I, R, I6R 0.92 0.87 0.85
Model-3 I, R, I6R, R6R 0.95 0.89 0.86
In the table I and R represent the descriptors of the inhibitors and the reverse transcriptases, respectively. I6R represents the cross-terms of descriptors of the inhibitor
and the reverse transcriptase. R6R represents the intra-reverse transcriptase cross-terms (i.e. cross-terms formed from descriptors of different amino acids in the reverse
transcriptase sequences).
doi:10.1371/journal.pone.0014353.t001
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the RT sequences in the test-set harbored, on average, eleven
mutations, the root mean squared error of prediction (RMSEP) was
as low as 0.25, which indicates a good model performance also for
heavily mutated virus variants.
Analysis of the role of individual amino acids in drug
resistance
Interpretation of a PLS model can be based on the analysis of
the coefficients of its regression equation. E.g., a positive value for
a coefficient for a z1-scale descriptor of an RT residue reveals that
a mutation to a more hydrophilic amino acid at this position
should (on the average) lead to decreased susceptibility to the
NRTIs, whereas a negative value indicates the opposite.
Comparisons of coefficients for all three z-scale descriptors of a
mutated sequence position thus allow delineation of physicochem-
ical and structural properties of amino acids that are responsible
for the change in susceptibility. This in turn allows for predictions
of the effect for mutations to any amino acid, including to such
that are not present in the virus variants in the model training
data-set.
The model also takes into account of interaction effects. A large
absolute value of a coefficient for a cross-term between RT and
inhibitor descriptors reveals that mutations of the represented
sequence residue induce large changes in the susceptibilities for
some particular inhibitors and not-so-large or even opposite
changes in the susceptibilities for other inhibitors. A large absolute
value of a coefficient for an intra-RT cross-term pinpoints
mutation pairs in the RT that regulate drug resistance in a
cooperative manner. However, a detailed interpretation that
includes the effects of cross-terms is difficult to describe in a written
account like this one. This is due to the large number of cross-
terms that needs be taken into account simultaneously. An
alternative, simpler approach is to use the whole regression
equation to predict drug susceptibilities of in-silico mutated virus
variants. This is done in Figure 2, which presents the predicted
changes in virus susceptibilities to the eight inhibitors due to single
point mutations in the wild type RT sequence. Shown are the 99
most frequent mutations; each of them was found in over 9% of
the isolates in the data-set.
The analysis of Figure 2 shows that 18 mutations reduce the
susceptibility to one or several NRTIs by more than 0.2 log units.
Some of these mutations afford inhibitor-specific effects. For
example, mutations L210W and T215Y/F are the most
deleterious for the thymidine analogues AZT and d4T, although
they also reduce the susceptibility to the other NRTIs. Similarly,
mutation M184V/I confers high resistance to the two structurally
Figure 1. Predictive ability of the HIV RT proteochemometric model. Illustrated is the external predictive ability of the proteochemometric
model (Model-3) for HIV drug susceptibility. The predicted versus measured susceptibility values are shown as red triangles. Goodness-of-fit of the
models (i.e. model data) are shown as blue triangles.
doi:10.1371/journal.pone.0014353.g001
Table 2. Prediction errors for the eight NRTIs in
proteochemometric model (Model-3).
NRTI Cross-validation results External predictions
RMSEP* Q1 Median Q3 RMSEP Q1 Median Q3
3TC 0.34 0.07 0.16 0.26 0.37 0.07 0.14 0.24
ABC 0.17 0.04 0.09 0.17 0.20 0.05 0.12 0.20
AZT 0.42 0.11 0.21 0.40 0.47 0.12 0.24 0.48
d4T 0.14 0.04 0.08 0.15 0.18 0.04 0.09 0.16
ddC 0.16 0.05 0.10 0.17 0.17 0.05 0.09 0.17
ddI 0.12 0.03 0.07 0.14 0.15 0.04 0.08 0.15
FTC 0.21 0.06 0.14 0.20 0.25 0.05 0.12 0.23
TDF 0.23 0.05 0.12 0.19 0.22 0.14 0.12 0.24
Average 0.22 0.06 0.12 0.21 0.25 0.07 0.13 0.23
*RMSEP – root mean squared error of prediction; Q1 – first quartile; Q3 – third
quartile.
doi:10.1371/journal.pone.0014353.t002
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to ABC, DDC, and DDI, but is unimportant or even beneficial for
AZT, d4T, and TDF. In contrast, some other mutations, such as
Q151M exert similar influence on most of NRTIs (except on 3TC
and FTC).
Figure 2 also discloses that quite many polymorphic mutations
(i.e. reflecting natural variations in the RT) as well as some of the
drug-pressure induced mutations may cause hyper susceptibility to
certain inhibitors. For example, mutations M184V/I and K65R,
which are the most deteriorating for 3TC and FTC, lead to
significant increase in susceptibility to AZT, thus suggesting a
benefit of combining these inhibitors. (However, co-formulated
3TC/AZT is only considered an alternative for first line therapy,
due to adverse effects of AZT [3]).
Online prediction of susceptibility resulting from
accumulated mutations
Although some single point mutations are sufficient to render
HIV resistant to individual drugs, escape from combination
regimens requires accumulation of multiple mutations, which
often appear in specific patterns. Cooperative effects that augment
drug resistance and/or compensate for loss of virus viability are
well known for many sets of mutations. E.g., a pathway that the
Figure 2. Effects of amino acid mutations on NRTI susceptibility. Illustrated are the changes in susceptibility to the eight NRTIs on single
amino acid mutations in the wild type HIV-1 RT. Shown are the decimal logarithms of the fold-changes in susceptibility calculated from the
proteochemometric model (Model-3). The green, yellow, and red areas in each panel represent susceptibilities falling, respectively, below the lower
cut-off, between the lower and upper cut-off, and above the upper cut-off levels for resistance; the cut-offs being as defined by the PhenoSense assay
documentation [http://www.monogramhiv.com/phenosense_report.aspx]. For some NRTIs, only one cut-off value is defined (shown in the figure by
omission of the yellow zone); the cut-off for ddC (a discontinued NRTI) is set arbitrarily for illustration purposes only.
doi:10.1371/journal.pone.0014353.g002
Modeling of RT
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mutation T215Y (or T215F), followed by M41L, which in turn is
followed by L210W [31]. As seen in the above-presented Figure 2,
the model does not find that mutations of residues 41 and 210
alone are influential on the susceptibility to d4T. However,
analysis of the regression equation reveals that large regression
coefficients have been given to the cross-terms between the
descriptors of these sequence positions and position 215, thus
indicating the possibility for strong cooperative effects within the
mutation triplet.
The number of all possible combinations of mutations in the RT
is immense and it is therefore beyond any practical possibility to
present their complete analysis in a written report. Therefore, to
facilitate predictions of the drug susceptibility of any HIV RT
variant bearing any clinically known or hypothetical mutation
pattern, we have set up a Web service to allow free public access to
our model. The service makes use of the novel XMPP protocol
[32], and a web page for invoking the service is available at [33].
Figure 3 presents screenshots of outputs from the web page,
illustrating the predicted susceptibilities for two patterns of
mutations: K65R+M184V (Panel A) and M41L+L210W+T215Y
(Panel B). We can there see that the double mutant
K65R+M184V is highly resistant to 3TC and FTC, while it
shows essentially unchanged susceptibility to d4T and TDF and is
hypersusceptible to AZT. On the other hand, the RT variant that
harbors the triple mutation M41L+L210W+T215Y is highly
resistant to AZT, while it shows an unchanged susceptibility to
ddC and ddI. By comparing the susceptibility profiles in the two
panels one can see that co-administration of AZT and ddI would
defer each of these resistance development pathways. On the other
hand, once all five mutations have accumulated in one HIV
variant, this would confer resistance to all of the available NRTIs,
which is a stage that poses a challenge for current anti HIV
therapies.
Discussion
In this study we applied proteochemometrics modeling to
analyze susceptibilities of multiple HIV mutants to eight clinically
used nucleoside/nucleotide analog reverse transcriptase inhibitors.
We represented the sequences of RT variants by physicochemical
property (z-scale) descriptors, rather than using letter codes for
amino acids. This approach enabled us to develop models that can
be used to assess the contributions of distinct physico-chemical
properties of sequence residues and their combinations for the
induction of resistance to RT inhibitors, and it allows us to
perform predictions for new RT sequences, provided that they fall
within the mutational space of polymorphic or drug-pressure
created mutants of the HIV-1 subtype B.
We assessed the predictive ability of the obtained PLS model by
cross-validation and by predicting a large independent test-set
comprising more than 200 RT mutants. The data-sets of earlier
studies addressing HIV-RT drug resistance vary both in size and
diversity. It is therefore impossible to straightforwardly compare
the performance of different computational techniques for
modeling the drug resistance from the literature data. However,
to the best of our judgment, the resolution of our PCM model,
being characterized by Q
2
ext=0.86 and RMSEP=0.25, is superior
compared with the resolution of the other hitherto best-performing
approaches, which analyzed the susceptibilities for each NRTI in
separate models [11–13]. This is best illustrated by comparing our
results with those of the previously reported models that were also
based on Stanford HIV DB data. Thus, in a study by Rhee et al.
[12] regression models were created for six NRTIs exploiting least-
squares regression (LSR), support vector regression (SVR), and
least angle regression (LARS) and the models had been evaluated
by 5-fold cross-validation. The mean values of squared correlation
coefficients between the actual and predicted logFDS values (i.e.
Q
2) were for these models, respectively, 0.36, 0.53, and 0.72. The
best results were achieved for 3TC (Q
2 being, respectively, 0.76,
0.84, and 0.93), whereas the worst predictions were for TDF (Q
2
being 0.01, 0.34, and 0.40) (However, it shall be noted that the
study of Rhee et al. comprised 639 isolates from the Stanford
database whereas our study contained 728 isolates so the results
are not entirely comparable). It is notable that no models were
created for ddC and FTC in the Rhee et al. study, which are
inhibitors for which comparatively little amount of data have been
collected in the Stanford HIV DB. While the reason for this could
be that ddC was discontinued in 2006, at least for FTC it could be
that insufficient data were available to create a model with the
methods chosen. Again this contrasts to the PCM approach, which
Figure 3. Prediction server for NRTI susceptibility. Shown are screenshots from the output from the web-page at www.hivdrc.org, utilizing the
web-service based on the proteochemometric model (Model-3). Shown are the predicted susceptibilities for the eight NRTIs covered by the model for
two sets of HIV mutant strains; K65R+M184V (panel A), and M41L+L210W+T215Y (Panel B). The web service takes an HIV-1 RT sequence as input and
predicts the virus susceptibility to the NRTIs using the unified proteochemometric model.
doi:10.1371/journal.pone.0014353.g003
Modeling of RT
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for which only little data is available.
In another recent study by Kjaer et al. [13], genotype-
phenotype correlation models were induced for all clinically used
NRTIs (except for ddC), by use of artificial neural networks
(ANN). The quality of ANN models had been estimated by 10-fold
cross-validation and the squared correlation coefficients between
the predicted and observed log susceptibility values (i.e. Q
2) ranged
from 0.56 (for TDF) to 0.88 (for 3TC), with the average value
being 0.74. The mean squared errors in these models ranged from
0.06 (corresponding to RMSEP~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:06
p
~0:25) for ddI to 0.98
(corresponding to RMSEP~0:99) for AZT, the average being
0.26 (corresponding to RMSEP~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:26
p
~0:51). Thus, although
exact comparisons of our results with the results of Kjaer et al. [13]
is impossible due to the differences in the analyzed data sets, the
listed Q
2 and RMSEP values points out that these models, which
just covers one inhibitor at a time, are inferior to the here
presented unified PCM model.
The web service developed herein has a potential to guide
inhibitor selection for combination regimens against particular RT
variants. Moreover, the model might also be used to derive general
guidelines for inhibitor combinations for HIV variants harboring
known sets of mutations. A pair-wise comparison of predicted
susceptibilities for the eight NRTIs for 728 viral isolates is shown
in Figure 4. For example, as can be seen from the figure,
combining 3TC with TDF gives high chances that the virus is
susceptible to at least one of the drugs. By contrast, co-
administration of 3TC with FTC gives no benefits according to
this analysis. Also, according to the analysis co-administration of
ABC with FTC is the least optimal among the recommended [3]
NRTI combinations for initial therapy (see Figure 4). In fact these
results arise due to that a mutation of residue 184 confers
resistance to both ABC and FTC. Moreover, aside from this
mutation, there is also a very high correlation between the
susceptibilities of the two drugs. By contrast, ABC and AZT have
different resistance patterns for most mutants (Fig. 4). As shown in
the figure, the analysis can be performed for any pair of drugs for
the whole mutational space of HIV RT, as well for any HIV
variant in a patient, and might therefore be used to find improved
treatment strategies.
Thus, to sum up we have here shown how proteochemometric
modeling can create a statistically valid unified model for
Figure 4. Pair-wise comparisons of NRTI susceptibilities. Shown are pair-wise comparisons of NRTI susceptibilities for mutant HIV variants,
predicted from the proteochemometric model (Model-3). The figure represents the computed susceptibilities for all mutation combinations occurring
in the data-set; red symbols represent predictions for the seven RT variants in the data-set that contained the double mutations K65R+M184V; green
symbols represent the susceptibilities for 153 variants containing the triple mutations M41L+L210W+T215; the blue symbols represent predictions for
568 other RT variants in the data-set retrieved from the Stanford HIV database.
doi:10.1371/journal.pone.0014353.g004
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and we have shown how it can be used to analyze resistance
patterns for combination treatments, thus giving a direction how
genome-based HIV therapy can be optimized. As our modeling
approach is completely general it can straightforwardly incorpo-
rate new NRTI inhibitors, and even so for new inhibitors where
little data has yet accumulated for their resistance patterns. We
have also made available a free web service where the model can
be used to predict the resistance pattern for existing and novel
mutated HIV RT variants for eight NRTIs. This web service can
be found at www.hivdrc.org.
Materials and Methods
Data-set
Phenotypic susceptibility data estimated by the PhenoSense
assay for the eight clinically approved NRTIs, Lamivudine (3TC),
Abacavir (ABC), Zidovudine (AZT), Stavudine (d4T), Zalcitabine
(ddC), Didanosine (ddI), Emtricitabine (FTC) and Tenofovir
(TDF), were retrieved from the Stanford HIV Drug Resistance
Database [34]. The PhenoSense assay measures the concentration
of the anti-HIV drug required to inhibit the replication rate of an
HIV isolate by 50%; i.e. the drug’s IC50 value. The susceptibility is
then expressed as the fold change in IC50 compared to a well-
characterized drug-sensitive reference virus, the NL4-3 HIV-1
strain. The resulting quotient (IC50 for the tested virus divided by
the reference IC50) is termed Fold Decrease in Susceptibility (FDS);
a value higher than 1 indicates a decrease in susceptibility. The
measurement range for the PhenoSense assay is for most NRTIs
0.1 to 200. For two NRTIs, namely AZT and 3TC, approximate
FDS values exceeding 200 were reported in some cases. For these
cases we set the values to FDS=200 for sake of the PCM
modeling.
The Stanford database also provides the sequences of the first
240 residues (i.e. the active site) of the RT sequences (i.e. data
obtained by the genotypic assay) along with the HIV susceptibility
data. The downloaded data-set comprised 728 HIV variants with
unique RT sequences, covering phenotypic assays for totally 4,495
drug-RT combinations. Sequences contained from one to 28 (on
the average 11) mutations, when compared to the HIV-1 subtype
B consensus sequence reported at the Stanford database [35]. (The
data-set used herein is available at http://www.hivdrc.org/data/
NRTI_PhenoSense_DataSet.xlsx, and can be used for fair
comparison of PCM with other modeling methods.)
For about 0.7% of the codons the genotyping had determined
that a mixture of two or more amino acids was present in the data
set. In most of these cases a mutated amino acid was found to be
present together with the wild-type amino acid; e.g. for the
resistance associated mutation M184V seventeen combinations
VM and eight combinations MV were reported. For creating
PCM models we used the description of the first-listed amino acid.
This was justified as we in a preliminary study had explored a
description utilizing the physico-chemical properties of all detected
amino acids. However, such a more complex description did not
give any improvement in the predictive ability of the resulting
models over using the first listed amino acid only. Accordingly we
did not use this approach in the subsequent modeling.
Some of the RT sequences contained so called ‘insertion
complexes’, which consist of a mutation followed by the insertion
of one or several amino acids; e.g. the insertion complex of residue
69, which reduces susceptibility to all NRTIs, was present in 10 of
728 sequences. Unfortunately, insertions were only indicated in
the Stanford database, providing no data on how many and which
amino acids that were inserted. Accordingly, we could not
compare the physico-chemical properties of the inserted amino
acid(s) and analyze their influence on the drug interactions. Since
the insertions could not be described explicitly the proteochemo-
metric model transferred their influence to the influence of the
underlying mutation.
Since the Stanford database does not provide patient identifiers
we do not know whether or not several sequences originate from
the same patient. This may give a risk that the model performance
is overestimated due to correlation of data originating from the
same patient. (However, this risk is inversely proportional to the
number of new mutations that have accumulated in a patient
between the repeated measurements). On the other hand, using
susceptibility data of virus strains evolving from the same patient
may allow better assessment of the contribution of individual
mutations on development of resistance, and may thus be
beneficial for model performance.
Numerical descriptions for PCM modeling
Description of Reverse Transcriptase. Of the 240
sequence residues of the RT recorded in the database, 75 were
invariant while 165 contained two or more different amino acids
in the set of the 728 RT sequences. We encoded each residue in
the mutated positions by three z-scale descriptors [36]. These z-
scales were obtained by principal component analysis [37] of 26
measured and calculated physicochemical and structural
properties of amino acids and can be interpreted as representing
hydrophobicity (z1), steric properties (i.e. size/shape; z2), and
electronic properties (z3) [36]. In this way, all the differences in the
physicochemical properties of the 728 RT sequences in the data-
set were characterized by 16563=495 descriptors. Prior to
further use, descriptors were mean-centered.
Description of RT Inhibitors. The 3D structures of the
active 5-triphosphate form of the organic compounds were
obtained by modeling with the Corina unit of the Tsar 3.3
(Accelrys Inc.) software. Compounds were then characterized by
molecular descriptors representing properties related to molecular
shape, flexibility, and ability to form different types of non-
covalent interactions. To this end descriptors of different classes
were calculated using Dragon 2.1 software (Talete S.r.1), as
follows: geometrical descriptors, charge and aromaticity indices,
constitutional descriptors, counts of functional groups and atom-
centered fragments, empirical descriptors, and molecular
properties. Descriptors were checked for mutual correlation;
when two or more descriptors were highly correlated (pairwise
r
2.0.95) only one of them was retained. In this way 58 molecular
descriptors were obtained for modeling [38] (see Table S1 for a
complete list of descriptors used).
Descriptors were mean centered and scaled to unit variance.
Further on, to reduce the number of descriptors and to eliminate
their mutual co-linearity, we performed principal component
analysis (PCA) [37] on the data set, which transformed all
descriptors into seven orthogonal principal components.
Reverse Transcriptase-Inhibitor and intra-Reverse
Transcriptase cross-terms. Protein-ligand interactions
depend on the complementarities of protein and ligand
properties. In PCM these can be represented by protein-ligand
cross-terms. We here calculated cross-terms by multiplying each of
the protein descriptors with each of the principal components for
the ligand descriptors, which yielded 76495=3,465 inhibitor-RT
cross-terms.
To account for eventual cooperative effects of mutations in the
RT, we also introduced intra-RT cross-terms. However, deriving
cross-terms between each and every one of the 495 RT descriptors
would have resulted in a huge amount of variables that could give
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model interpretations incomprehensible. We therefore elected to
derive cross-terms only between the descriptors of sequence
residues that appeared important for drug susceptibility. To this
end we calculated variable importance in the projection (VIP) for
RT descriptors in a preliminary model (i.e. Model-2, vide infra). A
VIP value larger than one indicates that a variable has higher than
average influence in the model [39]. Inspection of Model-2 (see
Results) showed that 48 RT descriptors obtained VIP.1. These
most influential descriptors were used to calculate cross-terms,
which accordingly gave 48647/2=1128 intra-RT cross-terms.
Prior to use in the modeling all cross-terms were mean-centered.
Since the number of cross-terms (i.e. 3,465 inhibitor-RT cross-
terms and 1,128 intra-RT cross-terms) greatly exceeded the
number of ordinary descriptors (i.e. 495 RT and 7 ligand
descriptors), block scaling was applied onto the block composed
of inhibitor-RT cross-terms (I6R block) and the block composed
of intra-RT cross-terms (R6R block). The scaling weights of these
two blocks of cross-terms were varied systematically starting from
zero and increasing them gradually until an optimal model was
obtained (i.e. the most predictive model according to the model’s
Q
2 parameter).
Correlation by partial least-squares projections to latent
structures
RT descriptors, inhibitor descriptors, and cross-terms were
correlated to the susceptibility data, expressed as the logarithmi-
cally transformed FDS values (logFDS), by partial least-squares
projections to latent structures (PLS). PLS finds a quantitative
relationship between a matrix of independent variables X and one
or several response variables (y vector or matrix) by simultaneously
projecting X and y to latent structures (PLS components) [29].
The directions and magnitudes of the influence of X variables on
the response y are revealed by coefficients in the regression
equation derived by a PLS model. PLS modeling was performed
using the orthogonal-PLS algorithm [40] as implemented in the
Simca-P 11 software (Umetrics AB).
The goodness-of-fit of a PLS models is characterized by the
fraction of explained variation of y (R
2). The predictive ability was
characterized by the fraction of the predicted y-variation (Q
2),
estimated by seven-fold cross-validation. Q
2 is calculated as:
Q2~1{
P N
n~1
(ypredicted, n{ymeasured, n)
2
P N
n~1
(ymeasured, n{ y y)
2
where  y yis the average of the measured outcome values for the N
objects in the data-set [39]. While the goodness of fit increases by
each extracted PLS component, the predictive ability typically
reaches a maximum and then declines when the model becomes
too complex.
Some earlier studies have indicated that a high value of Q
2 may
be insufficient evidence for a model to be highly predictive, when
only this parameter is used as a criterion for selecting model
parameters (e.g. adjusting scaling weights for cross-terms and
finding optimal number of PLS components) [41]. We therefore
also performed external validation of the PLS models. For these
validations the data-set was subdivided into a work-set (about 70%
of the RT sequences) and a prediction-set (about 30% of the RT
sequences). Splitting was performed in a random fashion by
assigning to the prediction-set all sequences for which the last digit
in the SeqID number in the Stanford database was 3, 6, or 9.
Supporting Information
Table S1 List of 58 molecular descriptors used to characterize
molecular properties of NRTIs for proteochemometric modeling
of HIV drug susceptibility.
Found at: doi:10.1371/journal.pone.0014353.s001 (0.06 MB
PDF)
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